Ceapro Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gilles R. Gagnon
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7824 – 51 Avenue NW Edmonton AB Canada T6E 6W2
- IPO Date
- Jan 8, 2021
- Website
- ceapro.com
- Similar Companies
- Business
- Ceapro Inc. is a Canadian biotechnology company headquartered in Edmonton, Alberta, specializing in the development and commercialization of active ingredients derived primarily from oats and other renewable plant sources for the health, cosmetics, nutraceutical, and pharmaceutical markets. The company manufactures and markets a portfolio of proprietary bioactive compounds, including oat beta glucan and avenanthramides, which serve as the core products used in skin care, personal care, and therapeutic applications. Its product range includes extracts for use in cosmeceuticals focused on skin hydration, anti-aging, wound healing, and anti-inflammatory properties, with applications also extending to animal health. Ceapro employs proprietary extraction and bioprocessing technologies such as Pressurized Gas Expanded Liquid (PGX) technology to develop its active ingredients. Recently, Ceapro has advanced its product pipeline with R&D progress, including a Phase 1-2a clinical study focused on avenanthramides and scaling up its PGX technology for nutraceutical and pharmaceutical applications. In 2024, the company announced a merger of equals with Aeterna Zentaris, aimed at creating a diversified biopharmaceutical company, expected to close in the second quarter of 2024. The merger represents a strategic expansion into broader biopharmaceutical markets alongside its established cosmeceutical and nutraceutical segments. Ceapro services human and animal health markets in Canada and internationally through partnerships and distribution networks. Founded in 1996, Ceapro leverages expertise in natural product chemistry, microbiology, biochemistry, immunology, and process engineering to develop innovative and scientifically supported natural health products and biopharmaceutical solutions. This strategic merger and ongoing clinical development position Ceapro for expanded market reach and product diversification in the health sciences sector.
Analyzing Ceapro (OTCMKTS:CRPOF) and ProMetic Life Sciences (OTCMKTS:PFSCF)
Head to Head Comparison: Synaptogenix (NASDAQ:TAOX) versus Ceapro (OTCMKTS:CRPOF)
Ceapro (CVE:CZO) Shares Down 11.8% – Time to Sell?
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris and Ceapro Complete Merger Transaction
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise